Head-to-head evidence
BPI-361175 vs TY-9591
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
BPI-361175
Developed by Betta Pharmaceuticals Co.
NCT05329298 · Phase 1/2 · status unknown
This is an open-label, non-randomized phase 1/2 dose-escalation and expansion study in which every participant received BPI-361175 with no placebo or active comparator, and no blinding was used. Results have not been posted, and because the design never included a controlled comparison, it cannot demonstrate a controlled treatment effect regardless.
TY-9591
Developed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPI-361175's landscape · TY-9591's landscape